ישראל - עברית - Ministry of Health

perrigo israel agencies ltd, israel - benzoin siam; hamamelis; ichthammol; titanium dioxide; zinc oxide - משחה - ichthammol 1.474 g / 100 g; zinc oxide 14.763 g / 100 g; hamamelis 0.984 g / 100 g; benzoin siam 0.1 g / 100 g; titanium dioxide 5.905 g / 100 g

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - benzoin siam; hamamelis; ichthammol; titanium dioxide; zinc oxide - משחה - ichthammol 1.474 g / 100 g; zinc oxide 14.763 g / 100 g; hamamelis 0.984 g / 100 g; benzoin siam 0.1 g / 100 g; titanium dioxide 5.905 g / 100 g - other anti-acne preparations for systemic use - local treatment of eczema, feet ulcers, mild burns and skin irritations.

ישראל - עברית - Ministry of Health

novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 0.5 mg - trametinib

ישראל - עברית - Ministry of Health

novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 2 mg - trametinib

ישראל - עברית - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

dexcel ltd, israel - lercanidipine hydrochloride - טבליה - lercanidipine hydrochloride 10.0 mg - lercanidipine - lercanidipine - hypertension. mild to moderate essential hypertension.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190